Brandon Folkes
Stock Analyst at Cantor Fitzgerald
(0.69)
# 2,933
Out of 4,412 analysts
27
Total ratings
21.05%
Success rate
-3.53%
Average return
Main Sectors:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Downgrades: Neutral | n/a | $3.15 | - | 1 | Nov 10, 2023 | |
| SMTI Sanara MedTech | Reiterates: Overweight | $59 | $32.35 | +82.38% | 4 | Sep 26, 2023 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $180 | $109.46 | +64.44% | 2 | Aug 22, 2023 | |
| VERU Veru Inc. | Maintains: Overweight | $30 → $22 | $1.27 | +1,632.28% | 2 | Dec 5, 2022 | |
| DERM Journey Medical | Initiates: Overweight | $9 | $3.40 | +164.71% | 1 | Feb 25, 2022 | |
| ALKS Alkermes | Upgrades: Overweight | $28 → $32 | $24.68 | +29.66% | 1 | Jan 27, 2022 | |
| RDHL RedHill Biopharma | Initiates: Overweight | n/a | $0.43 | - | 1 | Aug 31, 2021 | |
| RANI Rani Therapeutics Holdings | Initiates: Overweight | n/a | $6.68 | - | 1 | Aug 24, 2021 | |
| COLL Collegium Pharmaceutical | Downgrades: Neutral | n/a | $36.42 | - | 3 | Aug 6, 2021 | |
| PYPD PolyPid | Initiates: Overweight | n/a | $4.75 | - | 1 | Jul 30, 2021 | |
| TRVN Trevena | Initiates: Overweight | n/a | $0.39 | - | 1 | Aug 28, 2020 | |
| EBS Emergent BioSolutions | Maintains: Overweight | n/a | $1.92 | - | 3 | Jul 17, 2020 | |
| ANIP ANI Pharmaceuticals | Downgrades: Neutral | n/a | $65.36 | - | 2 | May 7, 2020 | |
| OPTN OptiNose | Reiterates: Overweight | n/a | $0.86 | - | 1 | Mar 5, 2020 | |
| EGRX Eagle Pharmaceuticals | Maintains: Neutral | n/a | $4.16 | - | 2 | Mar 2, 2020 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Overweight | n/a | $38.97 | - | 1 | Jul 12, 2018 |
Omeros
Nov 10, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.15
Upside: -
Sanara MedTech
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $32.35
Upside: +82.38%
Jazz Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $109.46
Upside: +64.44%
Veru Inc.
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $1.27
Upside: +1,632.28%
Journey Medical
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $3.40
Upside: +164.71%
Alkermes
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $24.68
Upside: +29.66%
RedHill Biopharma
Aug 31, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.43
Upside: -
Rani Therapeutics Holdings
Aug 24, 2021
Initiates: Overweight
Price Target: n/a
Current: $6.68
Upside: -
Collegium Pharmaceutical
Aug 6, 2021
Downgrades: Neutral
Price Target: n/a
Current: $36.42
Upside: -
PolyPid
Jul 30, 2021
Initiates: Overweight
Price Target: n/a
Current: $4.75
Upside: -
Trevena
Aug 28, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.39
Upside: -
Emergent BioSolutions
Jul 17, 2020
Maintains: Overweight
Price Target: n/a
Current: $1.92
Upside: -
ANI Pharmaceuticals
May 7, 2020
Downgrades: Neutral
Price Target: n/a
Current: $65.36
Upside: -
OptiNose
Mar 5, 2020
Reiterates: Overweight
Price Target: n/a
Current: $0.86
Upside: -
Eagle Pharmaceuticals
Mar 2, 2020
Maintains: Neutral
Price Target: n/a
Current: $4.16
Upside: -
Biohaven Pharmaceutical Holding Company
Jul 12, 2018
Maintains: Overweight
Price Target: n/a
Current: $38.97
Upside: -